| Item Type | Name |
|
Concept
|
Dose-Response Relationship, Drug
|
|
Academic Article
|
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.
|
|
Academic Article
|
No butts about it: put the fire out by lighting up.
|
|
Academic Article
|
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
|
|
Academic Article
|
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
|
|
Academic Article
|
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
|
|
Academic Article
|
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
|
|
Academic Article
|
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
|
|
Academic Article
|
Infliximab for the treatment of fistulas in patients with Crohn's disease.
|
|
Academic Article
|
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
|
|
Academic Article
|
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
|
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
|
Academic Article
|
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
|
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
|
Academic Article
|
The state of the art in the management of inflammatory bowel disease.
|
|
Academic Article
|
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
|
|
Academic Article
|
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
|
|
Academic Article
|
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
|
|
Academic Article
|
Controversies with aminosalicylates in inflammatory bowel disease.
|
|
Academic Article
|
Addicted to acid suppression.
|
|
Academic Article
|
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction.
|
|
Academic Article
|
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.
|
|
Academic Article
|
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study.
|
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
|
Academic Article
|
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
|
|
Academic Article
|
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
|
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
|
|
Academic Article
|
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.
|
|
Academic Article
|
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
|
|
Academic Article
|
Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
|
|
Academic Article
|
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.
|
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
|
Academic Article
|
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
|
|
Academic Article
|
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
|
|
Academic Article
|
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
|